Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metastatic colorectal cancer: current state and future directions.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2015

Fakih Marwan G

Abstract excerpt

Substantial improvements have been made in the management of metastatic colorectal cancer over the last two decades. The overall survival of patients diagnosed with unresectable metastatic colorectal cancer has increased from approximately 1 year during the era of fluoropyrimidine monotherapy to more than 30 months with the integration of multiple cytotoxic agents and targeted therapies. More effective...

Topics

Join the communities discussing this publication.

Angiogenesis Inhibitors
Antineoplastic Combined Chemotherapy Protocols
Molecular Targeted Therapy
Neoplasm Metastasis
Patient Selection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Precision Medicine

Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 25918280
DOI: 10.1200/JCO.2014.59.7633

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metastatic colorectal cancer: current state and future directions.PMID 25918280Read ↗

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities.Semantic proximity Read ↗

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.Semantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

BRAF-Directed Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular Targets for the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Personalizing medicine for metastatic colorectal cancer: current developments.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.Semantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in ReviewSemantic proximity Read ↗

Updates in the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.